info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
13
Nov
CymaBay Announces Participation at Three Upcoming Investor Conferences
12
Nov
CymaBay Announces Third Quarter Financial Results
10
Nov
CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
5
Nov
CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology (ACR) Annual Meeting, November 6 - 11
4
Nov
CymaBay to Announce Third Quarter 2015 Financial Results on Thursday, November 12
8
Oct
CymaBay Announces the Appointment of Robert J. Wills, Ph.D., as Chairman of the Board of Directors
3
Sep
CymaBay Therapeutics to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
10
Aug
CymaBay Announces Second Quarter 2015 Financial Results
6
Aug
CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents
3
Aug
CymaBay to Announce Second Quarter 2015 Financial Results on Monday, August 10
1
2
3
4
Next >>
Show All
Scroll
